Catalyst Pharmaceuticals, Inc.
Florida
United States
374 articles about Catalyst Pharmaceuticals, Inc.
-
Catalyst Pharmaceutical Partners Announces Second Quarter 2011 Financial Results
8/16/2011
-
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Efficacy Results Evaluating CPP-115 for the Treatment of Infantile Spasms
6/17/2011
-
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Efficacy Results Evaluating CPP-115 for the Treatment of Infantile Spasms
6/16/2011
-
Catalyst Pharmaceutical Partners Announces First Quarter 2011 Financial Results
5/16/2011
-
Catalyst Pharmaceutical Partners Announces Presentation to be Made at ARVO 2011 Conference
4/28/2011
-
Catalyst Pharmaceutical Partners to Present at the Antiepileptic Drug Trials XI Conference
4/21/2011
-
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-end 2010 Financial Results
4/1/2011
-
Catalyst Pharmaceutical Partners Announces Commencement of CPP-109 Investigator-Sponsored Study in Cocaine and Alcohol Co-Dependent Patients
3/29/2011
-
Catalyst Pharmaceutical Partners Announces Public Offering of Common Shares
3/9/2011
-
Catalyst Pharmaceutical Partners Promotes Steven R. Miller, Ph.D. to Chief Operating Officer
1/25/2011
-
Catalyst Pharmaceutical Partners to Present at the Biotech Showcase(TM) 2011 Conference
1/4/2011
-
Canadian Intellectual Property Office Grants Broad Patent for the Use of Catalyst Pharmaceutical Partners's Vigabatrin/CPP-109 for the Prevention of Addiction in Pain Management
12/9/2010
-
Catalyst Pharmaceutical Partners Initiates a Registration-Directed U.S. Phase II(b) Clinical Trial in Collaboration With The National Institute on Drug Abuse and Veteran's Administration Cooperative Studies Program
11/18/2010
-
Catalyst Pharmaceutical Partners Announces Third Quarter 2010 Financial and Operational Results
11/16/2010
-
Dr. Richard B. Silverman Joins Catalyst Pharmaceutical Partners Scientific Advisory Board
11/15/2010
-
Catalyst Pharmaceutical Partners Awarded $488,958 in Grants for its CPP-109 and CPP-115 Projects Under the Section 48D Therapeutic Discovery Program
11/4/2010
-
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Safety and Efficacy Results for CPP-115
11/1/2010
-
Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Safety and Efficacy Results for CPP-115
11/1/2010
-
Catalyst Pharmaceutical Partners Granted Orphan-Drug Designation for CPP-115 for the Treatment of Infantile Spasms
9/21/2010
-
Catalyst Pharmaceutical Partners Announces Second Quarter 2010 Financial Results
8/13/2010